BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sandborn WJ, Peyrin-Biroulet L, Quirk D, Wang W, Nduaka CI, Mukherjee A, Su C, Sands BE. Efficacy and Safety of Extended Induction With Tofacitinib for the Treatment of Ulcerative Colitis. Clin Gastroenterol Hepatol 2022;20:1821-1830.e3. [PMID: 33127596 DOI: 10.1016/j.cgh.2020.10.038] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 15.0] [Reference Citation Analysis]
Number Citing Articles
1 Kobayashi T, Hoshi M, Yuasa A, Arai S, Ikeda M, Matsuda H, Kim SW, Hibi T. Cost-Effectiveness Analysis of Tofacitinib Compared with Biologics in Biologic-Naïve Patients with Moderate-to-Severe Ulcerative Colitis in Japan. Pharmacoeconomics 2023. [PMID: 36884164 DOI: 10.1007/s40273-023-01254-x] [Reference Citation Analysis]
2 Ernest-Suarez K, Lu C. Editorial: real-world evidence of tofacitinib and vedolizumab in ulcerative colitis-are we one step closer to better positioning therapies after anti-TNF failure? Aliment Pharmacol Ther 2023;57:733-4. [PMID: 36821750 DOI: 10.1111/apt.17351] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Kutschera M, Novacek G, Reinisch W, Högenauer C, Petritsch W, Haas T, Moschen A, Dejaco C. Tofacitinib in the treatment of ulcerative colitis : A position paper issued by the Inflammatory Bowel Disease Working Group of the Austrian Society of Gastroenterology and Hepatology (ÖGGH). Wien Klin Wochenschr 2023;135:1-13. [PMID: 36454302 DOI: 10.1007/s00508-022-02110-2] [Reference Citation Analysis]
4 Herrera-deGuise C, Serra-Ruiz X, Lastiri E, Borruel N. JAK inhibitors: A new dawn for oral therapies in inflammatory bowel diseases. Front Med (Lausanne) 2023;10:1089099. [PMID: 36936239 DOI: 10.3389/fmed.2023.1089099] [Reference Citation Analysis]
5 Hans A, Battat R, Lukin DJ. Article Topic: Positioning Ulcerative Colitis Therapies in 2022 and Beyond. Curr Gastroenterol Rep 2022;24:157-70. [PMID: 36327029 DOI: 10.1007/s11894-022-00853-6] [Reference Citation Analysis]
6 Tofacitinib-Induktionstherapie bei Colitis ulcerosa kann verlängert werden. Z Gastroenterol 2022;60:1742-1744. [DOI: 10.1055/a-1923-8621] [Reference Citation Analysis]
7 Biedermann L, Dubinsky MC, Vermeire S, Fellmann M, Gardiner S, Hur P, Mundayat R, Panés J, Rubin DT. Health-Related Quality of Life Outcomes With Tofacitinib Treatment in Patients With Ulcerative Colitis in the Open-Label Extension Study, OCTAVE Open. Inflamm Bowel Dis 2022:izac222. [PMID: 36242764 DOI: 10.1093/ibd/izac222] [Reference Citation Analysis]
8 Li W, Zhao T, Wu D, Li J, Wang M, Sun Y, Hou S. Colorectal Cancer in Ulcerative Colitis: Mechanisms, Surveillance and Chemoprevention. Current Oncology 2022;29:6091-6114. [DOI: 10.3390/curroncol29090479] [Reference Citation Analysis]
9 Kahi CJ. Blue Notes. Clin Gastroenterol Hepatol 2022;20:1623-4. [PMID: 35878938 DOI: 10.1016/j.cgh.2022.05.004] [Reference Citation Analysis]
10 Parigi TL, Iacucci M, Ghosh S. Blockade of IL-23: What is in the Pipeline? J Crohns Colitis 2022;16:ii64-72. [PMID: 35553666 DOI: 10.1093/ecco-jcc/jjab185] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
11 Ferretti F, Cannatelli R, Monico MC, Maconi G, Ardizzone S. An Update on Current Pharmacotherapeutic Options for the Treatment of Ulcerative Colitis. J Clin Med 2022;11. [PMID: 35566428 DOI: 10.3390/jcm11092302] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 8.0] [Reference Citation Analysis]
12 Taxonera C, Carpio López D, Cabez Manas A, Hinojosa del Val JE. Clinical settings with tofacitinib in ulcerative colitis. Rev Esp Enferm Dig 2022. [DOI: 10.17235/reed.2022.8660/2022] [Reference Citation Analysis]
13 Zhang C, Zhu H, Jie H, Ding H, Sun H. Arbutin ameliorated ulcerative colitis of mice induced by dextran sodium sulfate (DSS). Bioengineered 2021. [PMID: 34783296 DOI: 10.1080/21655979.2021.2005746] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
14 D'Amico F, Magro F, Peyrin-Biroulet L, Danese S. Positioning Filgotinib in the Treatment Algorithm of Moderate to Severe Ulcerative Colitis. J Crohns Colitis 2022;16:835-44. [PMID: 34791103 DOI: 10.1093/ecco-jcc/jjab206] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]